Get the Stockscreener App
21.96
0.92%
0.20
After Hours:
22.20
0.24
+1.09%
Overview
News
Price History
Option Chain
Financials
Why BAX Down?
Discussions
Forecast
Stock Split
Dividend History
Baxter International Inc stock is traded at $21.96, with a volume of 22.65M.
It is up +0.92% in the last 24 hours and down -29.68% over the past month.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
See More
Previous Close:
$21.76
Open:
$21.51
24h Volume:
22.65M
Relative Volume:
4.46
Market Cap:
$11.27B
Revenue:
$11.89B
Net Income/Loss:
$-560.00M
P/E Ratio:
-19.96
EPS:
-1.1
Net Cash Flow:
$191.00M
1W Performance:
-24.85%
1M Performance:
-29.68%
6M Performance:
-32.56%
1Y Performance:
-39.02%
1-Day Range:
$21.33
$22.36
1-Week Range:
$21.33
$29.35
52-Week Range:
$21.33
$40.49
Baxter International Inc Stock (BAX) Company Profile
Name
Baxter International Inc
Sector
Industry
Phone
(224) 948-2000
Address
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
21.96 | 11.17B | 11.89B | -560.00M | 191.00M | -1.10 |
|
ISRG
Intuitive Surgical Inc
|
483.12 | 172.46B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
176.37 | 51.09B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
87.87 | 43.30B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
279.20 | 39.87B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
239.26 | 17.20B | 2.90B | 467.20M | 306.90M | 6.37 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Resumed | Goldman | Buy |
| Feb-24-25 | Upgrade | Argus | Hold → Buy |
| Feb-20-25 | Resumed | Barclays | Overweight |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-30-24 | Initiated | Goldman | Neutral |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Jan-06-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-03-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-15-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jun-24-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-18-22 | Reiterated | KeyBanc Capital Markets | Overweight |
| Feb-18-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-18-22 | Reiterated | Raymond James | Outperform |
| Feb-18-22 | Reiterated | Stifel | Buy |
| Feb-18-22 | Reiterated | UBS | Neutral |
| Feb-18-22 | Reiterated | Wells Fargo | Overweight |
| Feb-11-22 | Initiated | Goldman | Neutral |
| Jan-07-22 | Resumed | Citigroup | Buy |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-21 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-03-21 | Upgrade | Barclays | Equal Weight → Overweight |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-21 | Downgrade | UBS | Buy → Neutral |
| Dec-15-20 | Downgrade | Goldman | Buy → Neutral |
| Oct-01-20 | Upgrade | Citigroup | Neutral → Buy |
| Sep-04-20 | Downgrade | Argus | Buy → Hold |
| Jun-24-20 | Initiated | Oppenheimer | Outperform |
| Mar-19-20 | Upgrade | Stifel | Hold → Buy |
| Mar-18-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-02-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-17-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-26-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Apr-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-19 | Upgrade | Citigroup | Neutral → Buy |
| Jan-02-19 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Nov-02-18 | Upgrade | Argus | Hold → Buy |
| Oct-16-18 | Initiated | Barclays | Underweight |
| May-17-18 | Resumed | Piper Jaffray | Overweight |
| Feb-06-18 | Reiterated | Citigroup | Neutral |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-03-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
View All
Baxter International Inc Stock (BAX) Latest News
Baxter International (BAX) Falls to New Low on Disappointing Growth Forecast - Insider Monkey
Baxter stock cut to Neutral at Goldman Sachs (BAX:NYSE) - Seeking Alpha
Baxter cuts financial forecast while pausing infusion pump shipments - Fierce Biotech
Medical products maker Baxter cuts 2025 forecast; shares plunge to 19-year low - MSN
Baxter International (NYSE:BAX) Issues Q3 2025 Earnings Guidance - MarketBeat
Baxter International (NYSE:BAX) Releases FY 2025 Earnings Guidance - MarketBeat
Baxter International Inc. (NYSE:BAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Why is Baxter International Inc. stock attracting strong analyst attentionDaily Trading Guidance With Low Risk - jammulinksnews.com
Baxter Q2 2025 sales up 4% to USD 2.81B - Medical Buyer
Baxter International Inc (BAX) Q2 2025 Earnings Call Highlights: Strong EPS Growth Amid Operational Challenges - GuruFocus
Baxter International Inc. (NYSE:BAX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Baxter International Reports Steady Q2 2025 Growth - TipRanks
Baxter International’s Mixed Earnings Call Highlights Growth and Challenges - TipRanks
Baxter Healthcare – Building supply resilience for Australian healthcare - Manufacturers' Monthly
Baxter International Inc Options Spot-On: On July 31st, 222.65K Contracts Were Traded, With 75,527 Open Interest - 富途牛牛
Baxter International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Baxter lowers operational sales growth outlook to 3%-4% for 2025 amid Novum pause and fluid conservation - MSN
Baxter International's Q2 Earnings Miss and Strategic Crossroads: Navigating Operational Challenges and Leadership Transition in a Weak Industry Environment - AInvest
Baxter Shares Slide As Earnings And Forecast Disappoint - Finimize
Baxter halts infusion pump shipments, slashes 2025 sales forecast - Modern Healthcare
Baxter Stock Falls To 52-Week Low On Trimmed Annual OutlookBaxter Intl (NYSE:BAX) - Benzinga
Why Baxter (BAX) Stock Is Falling Today - Yahoo Finance
Baxter Still in Turnaround Mode, Awaiting Impact From New CEO - Morningstar
Baxter slumps as Medical Products & Therapies drive Q2 revenue miss - MSN
Baxter International Inc.'s 2025 Q2 Earnings: A Blueprint for Long-Term Growth Through Efficiency, Innovation, and Global Expansion - AInvest
Baxter International Q2 2025 Earnings Call Transcript: Key Highlights and Financial Outlook - AInvest
Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates - Yahoo Finance
RSI Alert: Baxter International Now Oversold - Nasdaq
BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down - TradingView
Baxter stock plunges as FDA scrutiny, lingering storm fallout damage outlook - Crain's Chicago Business
Baxter International stock slumps on Q2 miss (BAX:NYSE) - Seeking Alpha
Baxter International Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Hurricane Setback Batters Baxter International’s Earnings Forecast - Finimize
Baxter cuts forecast, misses estimates amid lingering hurricane impact on medical products unit - Reuters
Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Baxter International's Q2 2025 Earnings: A Tale of Revenue Growth and Profitability Struggles - AInvest
Baxter’s (NYSE:BAX) Q2 Earnings Results: Revenue In Line With Expectations But Stock Drops - Yahoo Finance
Baxter Q2 2025 slides trigger selloff despite strong Q1 performance By Investing.com - Investing.com Nigeria
Baxter Earnings Slip Below Forecasts As Outlook Gets Trimmed - Finimize
Baxter International Inc Reports Q2 2025 Earnings: GAAP EPS at $0.24, Revenue at $2.81 Billion, Both Below Estimates - GuruFocus
Baxter International Inc. Reports Second-Quarter 2025 Results - TradingView
Baxter Reports Second-Quarter 2025 Results - Business Wire
Pacer Advisors Inc. Sells 14,914 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International Inc. Approaches Psychological Resistance LevelStrong Buy With Technical Confidence Supported - metal.it
Baxter International (BAX) Earnings Outlook: A Buy Opportunity Amid Strong Guidance and Missed Potential? - AInvest
Baxter (BAX) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Wyckoff Accumulation Phase Possible in Baxter International Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
Baxter International BAX Q2 2025 Earnings Preview Upside Potential Amid Strong Segment Execution - AInvest
Is Baxter International Inc. a growth stock or a value stockFree Stock Watchlist For Fast Growth - jammulinksnews.com
Will Baxter International Inc. stock benefit from AI tech trendsHigh Yield Stock Screening Results Explained - metal.it
What is Baxter International Inc. company’s growth strategyPost Market Planner For Smart Trading - jammulinksnews.com
Baxter International Inc Stock (BAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):